GlassScriptPhysician profile
Paul J Aanderud
NPI 1255569273
$3,817.74
in general payments reported to CMS, 2019-2025
22 companies · $605 in 2025
The $605 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,536 · 2020: $235 · 2021: $193 · 2022: $345 · 2023: $626 · 2024: $278 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143 · Education: $366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.41 |
| Education | $366.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $866.59 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $657.13 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $530.54 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $310.97 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $240.18 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $210.51 | 2019-2020 | |
| Merz North America, INC. | $194.85 | 2019 | |
| Genzyme Corporation | $133.72 | 2019-2023 | |
| Pfizer INC. | $128.94 | 2019-2024 | |
| Galderma Laboratories, L.P. | $124.47 | 2019-2023 | Epsolay, Aklief, Oracea |
| Ucb, INC. | $108.89 | 2019-2025 | Bimzelx |
| Biofrontera INC. | $51.48 | 2019-2025 | Ameluz |
| Elekta, INC. | $50.05 | 2024 | Elekta Medical Linear Accelerator |
| Almirall LLC | $47.42 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $34.23 | 2019-2023 | Blu-U, Odomzo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.44 | 2019-2021 | |
| Incyte Corporation | $24.64 | 2022 | |
| Celgene Corporation | $20.10 | 2019 | |
| Arcutis Biotherapeutics, INC. | $18.23 | 2025 | Zoryve |
| Amgen INC. | $14.57 | 2023 | Otezla |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Organon LLC | $7.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Aanderud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.